Five Prime Therapeutics, Inc. (NASDAQ:FPRX)‘s stock had its “hold” rating restated by equities researchers at BMO Capital Markets in a research report issued on Friday. They currently have a $39.00 target price on the biotechnology company’s stock. BMO Capital Markets’ price target suggests a potential upside of 10.36% from the company’s current price.

Other research analysts have also issued research reports about the company. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price target on shares of Five Prime Therapeutics in a research report on Thursday, June 8th. Royal Bank Of Canada assumed coverage on Five Prime Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $41.00 price target for the company. BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Finally, ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Five Prime Therapeutics presently has a consensus rating of “Hold” and an average target price of $54.86.

Shares of Five Prime Therapeutics (NASDAQ FPRX) traded up 0.28% during midday trading on Friday, reaching $35.34. The company had a trading volume of 290,726 shares. Five Prime Therapeutics has a 52 week low of $25.97 and a 52 week high of $60.98. The firm’s market capitalization is $988.99 million. The stock has a 50-day moving average of $31.18 and a 200 day moving average of $32.04.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.15) by ($0.43). The company had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The company’s revenue was down 16.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.49) EPS. On average, analysts anticipate that Five Prime Therapeutics will post ($5.16) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Five Prime Therapeutics, Inc. (FPRX) Stock Rating Reaffirmed by BMO Capital Markets” was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/22/five-prime-therapeutics-inc-fprx-stock-rating-reaffirmed-by-bmo-capital-markets.html.

Several large investors have recently made changes to their positions in the business. AWM Investment Company Inc. boosted its position in shares of Five Prime Therapeutics by 25.0% during the second quarter. AWM Investment Company Inc. now owns 100,000 shares of the biotechnology company’s stock valued at $3,011,000 after buying an additional 20,000 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Five Prime Therapeutics by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock valued at $646,000 after buying an additional 397 shares during the period. State Street Corp boosted its position in shares of Five Prime Therapeutics by 8.4% during the second quarter. State Street Corp now owns 1,354,597 shares of the biotechnology company’s stock valued at $40,782,000 after buying an additional 105,077 shares during the period. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Five Prime Therapeutics by 3.0% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,227 shares of the biotechnology company’s stock valued at $518,000 after buying an additional 494 shares during the period. Finally, Fred Alger Management Inc. boosted its position in shares of Five Prime Therapeutics by 25.0% during the second quarter. Fred Alger Management Inc. now owns 15,000 shares of the biotechnology company’s stock valued at $452,000 after buying an additional 3,000 shares during the period. Institutional investors and hedge funds own 84.05% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.